|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 106.82 CHF | +0.17% |
|
+2.46% | +20.43% |
Evolution of the Average Target: Novartis AG
Evolution of the Target Price: Novartis AG
Changes in Analyst Recommendations: Novartis AG
| Consensus | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Objective/dr gap | ||
|---|---|---|---|---|---|---|
 | +1.2% | |||||
| +6.65% | |||||
| +0.89% | |||||
| +9.16% | |||||
| +0.24% | |||||
| +9.84% | |||||
| +7.77% | |||||
| +30.7% | |||||
| +0.94% | |||||
| +7.79% | |||||
| Average | +7.52% | |||||
| Weighted average by Cap. | +6.64% |
Analysts' Consensus
Analyst Consensus Detail
Consensus revision (last 18 months)
Analysts covering the company
| JPMORGAN | Richard Vosser |
| alphavalue | Abhishek Raval |
| Morgan Stanley | |
| AlphaValue/Baader Europe | |
| BARCLAYS | Shirley Chen |
| UBS | Matthew Weston |
| BERNSTEIN RESEARCH | Florent Cespedes |
| BERENBERG | |
| Morningstar | |
| Intron Health | |
| DZ BANK | Elmar Kraus |
| JEFFERIES | Michael Leuchten |
| DEUTSCHE BANK RESEARCH | Emmanuel Papadakis |
| Bank Vontobel AG | |
| Goldman Sachs | |
| BNP Paribas Exane | |
| DA Davidson | |
| HSBC | |
| Octavian AG | |
| Jefferies & Co. | |
| Deutsche Bank Securities | |
| Baader Bank | |
| Berenberg Bank | |
| BMO Capital | |
| Kepler Capital Markets | |
| Societe Generale | |
| Redburn | |
| Stifel Nicolaus | |
| BNP Paribas | |
| Barrington Research | |
| International Strategy & Investment Group | |
| Credit Suisse | |
| ODDO BHF | |
| Zacks Equity Research | |
| Bank of America Securities/Merrill Lynch | |
| Kepler Cheuvreux | |
| Wolfe Research | |
| AltaCorp Capital | |
| DEUTSCHE BANK | Emmanuel Papadakis |
| Exane BNP Paribas | |
| Bryan, Garnier & Co. | |
| Moody's Investors Service | |
| Dundee | |
| Exane BNP | |
| Bernstein | |
| Argus | |
| Cowen | |
| BRYAN GARNIER | Eric Le Berrigaud |
| LIBERUM CAPITAL | Graham Doyle |
| BANK OF AMERICA (BOFA) | Graham Parry |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- NOVN Stock
- Consensus Novartis AG
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition